Certain cell therapies that hold promise for treating autoimmune diseases like multiple sclerosis might work not because of the way the cells live in the body during treatment, but because of how they die. A better understanding of how these cell therapies work “is important in designing treatment protocols…

First Patient Dosed in Phase 1 Trial of IMS001 Therapy IMS001 is an investigational treatment that uses mesenchymal stem cells (MSC) — cells derived from human embryos. Preclinical studies have shown that IMS001 has the ability to stabilize an overactive immune system, as is the case in people with…

ImStem Biotechnology announced that the first patient in its Phase 1 clinical trial for IMS001, an investigational treatment for multiple sclerosis (MS), has been dosed at the Shepherd Center in Atlanta. The trial (NCT04956744) is recruiting participants with an MS diagnosis ages 18 to 65. More information…

The U.S. Food and Drug Administration (FDA) has given the green light to a Phase 2 clinical trial that will assess the efficacy of using adult mesenchymal stem cells (MSCs) to treat the symptoms of mild to moderate multiple sclerosis (MS). The non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF),…

BrainStorm Cell Therapeutics announced the Cleveland Clinic is the first clinical site contracted in the United States for the Phase 2 multi-center study evaluating the company’s NurOwn mesenchymal stem cell (MSC) therapy in individuals with progressive multiple sclerosis (MS). “We are very excited to announce The Mellen Center for…

The U.S. Food and Drug Administration (FDA) has approved BrainStorm Cell Therapeutics‘ request to open a Phase 2 clinical trial testing the safety and effectiveness of its proprietary NurOwn mesenchymal stem cell (MSC) treatment in progressive multiple sclerosis (MS) patients. The request was in the form of Investigational New Drug…

On June 2, a symposium titled “Cell-based therapies in MS” was presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). One of the speakers was Dr. Mark S. Freedman, professor of medicine (neurology) at the University of Ottawa in Canada, who discussed the use of stem…

Startup biotech company ImStem Biotechnology is looking to raise additional funding for their upcoming clinical trials after publishing promising research on a unique stem-cell treatment used on mice with multiple sclerosis.  The company has already received previous funding…